Originally conceived (no pun intended) as Compound ICI 46,474, tamoxifen was synthesised as part of a project to develop a contraceptive pill ... and screenings to identify at-risk women with ...

The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...

In conversation with experts, we’ll break down what you need to know about the most commonly prescribed type of contraception in the United States: the pill. “The most common and most familiar ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

An Indiana toddler died after ingesting a suboxone pill she found in a backpack at a thrift store, according to her family. The 18-month-old child, Azana Trentman, became unresponsive and was ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...

The pill is made by Novo Nordisk, the same company that makes Ozempic. The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. And even when he got the drug, he waited a month before using it.

Whether you’re interested in the pill, or you want to learn more about other forms of contraception (such as the implant, IUD or patch), there will never be a one-size-fits-all approach to ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage ... Kisqali will be administered as an oral pill. It will be prescribed for three weeks, with a one-week break, to be ...

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...